INmune Bio Narrows Q1 Loss, Targets Mid-2026 UK/EU CORDStrom Filings and Q4 FDA Submission
Summary
Inmune Bio reported a narrowed net loss for Q1, primarily attributed to lower research and development expenses, though the company generated no revenue during the quarter. This financial update is particularly significant given the company's recent 10-K filing, which expressed substantial doubt about its ability to continue as a going concern. Despite the ongoing losses, the company outlined key regulatory milestones for its CORDStrom program, anticipating submissions to UK and EU regulators by mid-summer 2026, followed by a BLA submission to the FDA in Q4 2026. These upcoming regulatory catalysts are vital for Inmune Bio's long-term prospects and could provide a path to address its financial viability concerns. The market will be watching for progress on these filings and the additional imaging analyses from the XPro Alzheimer's trial.
At the time of this announcement, INMB was trading at $1.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $38M. The 52-week trading range was $1.09 to $11.64. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Reuters.